Polymorphisms in

Sorafenib-treated patients display a substantial variation in the incidence of toxicity. We aimed to investigate the association of genetic polymorphisms with observed toxicity on sorafenib. We genotyped 114 patients that were treated with sorafenib at the Erasmus MC Cancer Institute, the Netherland...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacogenomics 2016-09, Vol.17 (14), p.1483-1490
Main Authors: Bins, Sander, Lenting, Anne, El Bouazzaoui, Samira, van Doorn, Leni, Oomen-de Hoop, Esther, Eskens, Ferry ALM, van Schaik, Ron HN, Mathijssen, Ron HJ
Format: Article
Language:English
Subjects:
drug transporters
hepatocellular carcinoma
pharmacogenetics
renal cell cancer
sorafenib
toxicity
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sorafenib-treated patients display a substantial variation in the incidence of toxicity. We aimed to investigate the association of genetic polymorphisms with observed toxicity on sorafenib. We genotyped 114 patients that were treated with sorafenib at the Erasmus MC Cancer Institute, the Netherlands, for and . The (rs8175347) polymorphism was associated with hyperbilirubinemia and treatment interruption. Polymorphisms in (rs2306283, rs4149056) were associated with diarrhea and thrombocytopenia, respectively. None of the investigated polymorphisms was associated with overall or progression-free survival in hepatocellular cancer patients. Polymorphisms in and are associated with several different sorafenib side effects.
ISSN:1462-2416
1744-8042
DOI:10.2217/pgs-2016-0063